Obesity
General Medicine · Topic 14
Source: NMC CBME Curriculum 2024 · Volume II · General Medicine · Topic 14 · combined PDF page 304
Practice questions
- A clinician is applying the 2025 VA/DoD recommendation for routine adult screening for overweight and obesity to an Asian adult. At what BMI should screening begin under this recommendation?
- For routine adult screening, which approach is suggested by the 2025 VA/DoD guideline to refine obesity-related risk after BMI screening?
- A patient with obesity asks whether lifestyle treatment is still relevant if medication is prescribed. Which response best aligns with the 2025 VA/DoD guideline?
- A patient with obesity has begun a comprehensive lifestyle intervention but has not yet achieved the desired weight loss. Which statement about adding pharmacotherapy is most consistent with the 2025 VA/DoD guideline?
- A patient has achieved clinically useful weight loss with an anti-obesity medication and asks to stop it to avoid future weight regain. Which approach is supported by the 2025 VA/DoD guideline?
- A nonpregnant adult with BMI 32 kg/m² seeks outpatient pharmacologic treatment for weight management. According to the 2026 ACP guideline, which medications are listed as first-line options when used with lifestyle modifications?
- A nonpregnant adult has BMI 29 kg/m² and type 2 diabetes and seeks outpatient treatment for weight management. Which statement best reflects the 2026 ACP guideline?
- A nonpregnant adult with BMI 28 kg/m² has obstructive sleep apnea and requests medication for weight management. Which is the most accurate interpretation of the 2026 ACP recommendation?
- A clinician and a nonpregnant adult with obesity are discussing medication options. Which option is listed as second-line by the 2026 ACP guideline?
- A patient with obesity and established cardiovascular disease is considering phentermine-topiramate for weight management. Which issue is specifically highlighted in the 2026 ACP guideline?
- A reproductive-age patient is considering phentermine-topiramate for weight management. Which monitoring issue is specifically highlighted by the ACP guideline?
- A patient with obesity and a history of suicidal ideation is considering naltrexone-bupropion. Which concern should be included in the medication discussion according to the ACP guideline?
- A patient and clinician are deciding whether to start or switch an anti-obesity medication. Which set of factors is most consistent with the ACP guideline's recommended discussion?
- A patient with obesity has an inadequate response to a prescribed weight-management medication, and clinician and patient are considering switching. What approach best reflects the 2026 ACP guideline?
- Which statement about the evidence certainty for medications in the 2026 ACP guideline is accurate for nonpregnant adults with obesity?
- A woman with endometrial intraepithelial neoplasia and obesity is discussing weight-management options with her care team. Which statement best reflects the SGO/SAGES clinical practice statement?
- A patient with obesity and endometrial cancer is being assessed for definitive cancer surgery but currently has elevated operative risk. What potential role for metabolic and bariatric surgery is described in the SGO/SAGES statement?
- Which statement best characterizes the relationship between obesity and endometrial cancer described in the SGO/SAGES clinical practice statement?
- Which care-planning approach is emphasized for women with endometrial intraepithelial neoplasia or endometrial cancer and obesity?
- A patient with obesity-related HFpEF has exertional limitation despite attention to volume status. Which mechanistic description best fits the phenotype summarized in a 2026 systematic review?
- In the practical therapeutic framework for obesity-driven HFpEF summarized in a 2026 systematic review, which pharmacologic class is considered the foundation because it has the most mature outcome data across the preserved-ejection-fraction spectrum?
- A patient with obesity-related HFpEF asks what benefit has been reported with semaglutide in dedicated trials of this phenotype. Which response is best supported by the 2026 systematic review?
- In the 2026 systematic review of obesity-driven HFpEF, which additional outcome was reported with tirzepatide?
- A patient with obesity and pre-existing gastroesophageal reflux disease is considering a bariatric procedure. In a 2026 network meta-analysis, which procedure had greater odds of GERD improvement than sleeve gastrectomy?
- Which conclusion about smartphone apps supporting adults after obesity treatment is most consistent with a 2026 systematic review?